Benevolent AI (XAMS:BAI) Debt-to-Equity : 0.05 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Benevolent AI Debt-to-Equity?

Benevolent AI's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1.07 Mil. Benevolent AI's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €4.44 Mil. Benevolent AI's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €109.43 Mil. Benevolent AI's debt to equity for the quarter that ended in Dec. 2023 was 0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Benevolent AI's Debt-to-Equity or its related term are showing as below:

XAMS:BAI' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.08 Max: 0.14
Current: 0.05

During the past 6 years, the highest Debt-to-Equity Ratio of Benevolent AI was 0.14. The lowest was 0.05. And the median was 0.08.

XAMS:BAI's Debt-to-Equity is ranked better than
72.98% of 1066 companies
in the Biotechnology industry
Industry Median: 0.15 vs XAMS:BAI: 0.05

Benevolent AI Debt-to-Equity Historical Data

The historical data trend for Benevolent AI's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Debt-to-Equity Chart

Benevolent AI Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.09

0.08

0.14

0.05

Benevolent AI Semi-Annual Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial				0.14	0.05	0.05	0.05	0.05

Competitive Comparison of Benevolent AI's Debt-to-Equity

For the Biotechnology subindustry, Benevolent AI's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Benevolent AI's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benevolent AI's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Benevolent AI's Debt-to-Equity falls into.

Benevolent AI Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Benevolent AI's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.074	+	4.438)	/	109.426
	=	0.05

Benevolent AI's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.074	+	4.438)	/	109.426
	=	0.05

Benevolent AI (XAMS:BAI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Benevolent AI Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Benevolent AI's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Benevolent AI (XAMS:BAI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (XAMS:BAI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BAIVF:USA 2XA:Germany

Address

4-8 Maple Street, London, GBR, W1T 5HD

Website

https://www.benevolent.com

Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.

Benevolent AI (XAMS:BAI) Headlines

No Headlines